Literature DB >> 8599870

cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.

M G Ormerod1, C O'Neill, D Robertson, L R Kelland, K R Harrap.   

Abstract

We have studied the effects of the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-platin) on three human ovarian carcinoma cell lines - one sensitive to the drug (CH1), one with acquired resistance (CH1cisR) and one with intrinsic resistance (SKOV-3). Previous work has shown that the 50% inhibitory concentrations (IC50 values) after a 2-h exposure to the drug are: CH1, 2.5 microM; CH1cisR, 7.5 microM; and SKOV-3, 33 microM. Despite the variation in sensitivity, the amount of Pt bound to DNA and the rate of removal of Pt was similar for the three lines. There were significant differences in the rates of formation of DNA cross-links but these were not large enough to account for the high resistance of the SKOV-3 line. We have reported that in the L1210 murine leukaemia cell line there are two mechanisms of cisplatin-induced cell death - one of which involves apoptosis. In this paper, we report on an investigation into whether sensitivity to apoptosis played a role in the resistance of these ovarian lines toward cisplatin. After a 2-h incubation with the drug, cells from the three lines showed evidence of death through apoptosis. The cells detached from the culture dish in a time- and dose-dependent fashion. These cells morphologically were quite distinctive from the attached cells and showed changes in their chromatin structure indicative of apoptosis. Their DNA had not been degraded into oligonucleosomal fragments (200 bp and multiples thereof) but had been cut into larger fragments (30 kilobase pairs, kbp) of a size associated with chromatin domains (chromatin loops). At equitoxic doses of drug, the quantity of cells undergoing apoptosis was similar for the three cell lines. The most prominent effect on cell-cycle kinetics was a slowdown in S-phase transit during which the cells underwent apoptosis. Cells that successfully completed the S phase subsequently suffered a temporary G2 block. We propose that the sensitivity of these cell lines to cisplatin was governed by their ability to handle damage caused by platination of the DNA and that the major mechanism of cisplatin-induced cell death in all three cell lines was the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599870     DOI: 10.1007/s002800050413

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  55 in total

1.  Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis.

Authors:  R J Collins; B V Harmon; G C Gobé; J F Kerr
Journal:  Int J Radiat Biol       Date:  1992-04       Impact factor: 2.694

2.  The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells.

Authors:  R Bøe; B T Gjertsen; O K Vintermyr; G Houge; M Lanotte; S O Døskeland
Journal:  Exp Cell Res       Date:  1991-07       Impact factor: 3.905

3.  Improved program for the analysis of DNA histograms.

Authors:  M G Ormerod; A W Payne; J V Watson
Journal:  Cytometry       Date:  1987-11

Review 4.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

5.  Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.

Authors:  L R Kelland; P Mistry; G Abel; S Y Loh; C F O'Neill; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes.

Authors:  D L Evans; C Dive
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

7.  A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.

Authors:  R P Perez; A K Godwin; L M Handel; T C Hamilton
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

Authors:  N Sheibani; M M Jennerwein; A Eastman
Journal:  Biochemistry       Date:  1989-04-04       Impact factor: 3.162

9.  The role of apoptosis in cell killing by cisplatin: a flow cytometric study.

Authors:  M G Ormerod; R M Orr; J H Peacock
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

10.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Authors:  C A Hills; L R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more
  19 in total

1.  Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells.

Authors:  Dae-Hee Lee; Clifford Kim; Lin Zhang; Yong J Lee
Journal:  Biochem Pharmacol       Date:  2008-02-29       Impact factor: 5.858

2.  As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.

Authors:  Lionel Berthoux; Greg J Towers; Cagan Gurer; Paolo Salomoni; Pier Paolo Pandolfi; Jeremy Luban
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis.

Authors:  Bassant M Barakat; Qi-En Wang; Chunhua Han; Keisha Milum; De-Tao Yin; Qun Zhao; Gulzar Wani; El-Shaimaa A Arafa; Mohamed A El-Mahdy; Altaf A Wani
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

4.  Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.

Authors:  Elizabeth M Freeburg; Alicia A Goyeneche; Carlos M Telleria
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

5.  Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells.

Authors:  Tereza Muchova; Jitka Pracharova; Pavel Starha; Radana Olivova; Oldrich Vrana; Barbora Benesova; Jana Kasparkova; Zdenek Travnicek; Viktor Brabec
Journal:  J Biol Inorg Chem       Date:  2013-05-15       Impact factor: 3.358

6.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

7.  Developing central nervous system and vulnerability to platinum compounds.

Authors:  G Bernocchi; M G Bottone; V M Piccolini; V Dal Bo; G Santin; S A De Pascali; D Migoni; F P Fanizzi
Journal:  Chemother Res Pract       Date:  2011-02-15

8.  Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.

Authors:  Carlos D Gamarra-Luques; Alicia A Goyeneche; Maria B Hapon; Carlos M Telleria
Journal:  BMC Cancer       Date:  2012-06-22       Impact factor: 4.430

9.  Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.

Authors:  V Cepero; B García-Serrelde; V Moneo; F Blanco; A M González-Vadillo; A Alvarez-Valdés; C Navarro-Ranninger; A Carnero
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

10.  Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.

Authors:  Elizabeth M Freeburg; Alicia A Goyeneche; Erin E Seidel; Carlos M Telleria
Journal:  Cancer Cell Int       Date:  2009-02-17       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.